FDA gives Johnson & Johnson's Erleada a quick push over the finish line with first-ever nonmetastatic prostate cancer nod

Johnson & Johnson is fighting a patent decision that would open up its older prostate cancer drug Zytiga to early generic competition. (J&J)

Johnson & Johnson just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer. J&J’s new drug apalutamide won FDA approval months ahead of its scheduled decision date, and it’s now ready to scoop up market share before its rivals win a new, similar indication for their treatment, Xtandi.

Now known as Erleada, apalutamide is the first therapy to win approval for nonmetastatic prostate cancer, the FDA said, and the first to get a green light based on metastasis-free survival numbers. It’s also J&J’s follow-up to its blockbuster prostate cancer drug Zytiga, which scored a few approval firsts of its own but now faces an earlier-than-expected battle against generics later this year.

Speaking of battles, Erleada comes to the market with data showing “a robust effect” on metastasis-free survival, Richard Pazdur, M.D., chief of the FDA’s Office of Hematology and Oncology Products, said in a statement on Wednesday.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson & Johnson

It’s data that was released in detail just last week at ASCO’s Genitourinary Cancers Symposium, the same meeting where similar Xtandi data made its debut. In a trial called Spartan, Erleada delivered 40.5 metastasis-free months, a 24.3-month improvement over current therapy.

Xtandi’s results in its Prosper trial didn't match up exactly—and true comparisons are only possible in head-to-head clinical trials—but they were close. The Pfizer-Astellas drug, added to hormonal therapy, held off metastasis by 36.6 months at the median, a 21.9-month improvement over hormonal treatments alone.

RELATED: The top 15 best-selling cancer drugs in 2022 - Xtandi

“We recognize that cross-trial comparisons are fraught with issues, but Spartan and Prosper in our view essentially delivered identical outcomes,” Barclays analyst Geoff Meacham, Ph.D., wrote in a note on Monday. His firm predicts that Erleada can peak at $1.3 billion, well within blockbuster territory.

That’s not as much as Zytiga has delivered; the drug brought in $2.5 billion last year. But as Barclays noted, “commercial execution [is] the key to [the] next leg of growth” not only for Erleada but also for Xtandi. And with its early approval in hand, J&J can get going on promoting its drug to doctors well ahead of Pfizer and Astellas.

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.